Close Menu

GenMark Diagnostics: James McNally

Jan 21, 2020

GenMark Diagnostics said that on Jan. 9, it notified James McNally, its senior vice president of marketing and business development, that his employment with the firm would cease on Jan. 10.

In a filing with the US Securities and Exchange Commission, GenMark also said that on Jan. 14, it entered into a separation agreement and general release with McNally. In accordance with the agreement, McNally is entitled to benefits, including a gross lump sum payment equal to six months of his base salary in effect as of the separation date; an amount equal to McNally’s target bonus percentage under the firm's 2019 bonus plan multiplied by a percentage tied to the achievement of the company-level performance targets under the plan; and an aggregate of 35,702 restricted stock units held by McNally as of the separation date.

More Like This

Jul 14, 2020

Predictive Oncology: Nancy Chung-Welch, Charles Nuzum, Greg St. Clair

Predictive Oncology has appointed Nancy Chung-Welch, Charles Nuzum, and Greg St. Clair as independent directors to the firm. While Nuzum will serve on Predictive's audit committee, the firm noted that the other directors will join committees as soon as possible. 

Chung-Welch currently serves as an independent consultant advising life science companies and institutional investors. She previously served as director of business development at Cell Signaling Technology, as well as a director of business development at Thermo Fisher Scientific. She has also served as a technical marketing manager at Fisher Scientific.

Nuzum currently provides project-based financial consulting services to companies including McKesson, BioMarin, and AutoDesk. He serves on the board of directors of Dakshidin, NanoSynx, and Worldwide Structures. He previously cofounded and served as CFO of Tyburn Group. Prior to Tyburn, Nuzum served as controller of Merck KgaA pharmaceutical manufacturing subsidiary Dely. Before working at Dely, he served as cofounder, executive VP, and CFO of SCV Financial Services. 

St. Clair is the founder and managing member of SunStone Consulting. Prior to SunStone, he served as national VP of CGI, ImrGlobal, and Orion Consulting. He also served as a national director for Coopers & Lybrand. 

Jul 09, 2020

Teknova: Stephen Gunstream

Teknova has appointed Stephen Gunstream as its CEO. Gunstream will replace Ted Davis, the firm's founder and retiring CEO. Gunstream previously served as VP and general manager of BD Biosciences' research and clinical business. Prior to BD, Gunstream served as chief commercial officer at Integrated DNA Technologies.  

Jul 08, 2020

Notable: Joseph Wagner

Precision oncology company Notable has hired Joseph Wagner as CSO. A pharmacologist by training with a history in the biotech industry, Wagner had been executive director of the University of California Drug Discovery Consortium. He previously held executive positions at BriaCell Therapeutics, OncoCyte, and Cell Targeting. Wagner will report directly to Notable CEO Laurie Heilmann. 

Jul 07, 2020

ReadCoor: Dennis Flannelly

Multi-omic spatial sequencing company ReadCoor has appointed Dennis Flannelly to its board of directors. Flannelly is currently head of precision medicine for US oncology at Merck, known as MSD outside of the US and Canada. Prior to joining Merck, Flannelly served in leadership roles at PerkinElmer, most recently as VP and general manager of the immunodiagnostics business, and previously as VP of maternal-fetal health. Flannelly has also served as global director of clinical marketing for Thermo Fisher Scientific's immunodiagnostics business. He also served as the head of US marketing for Thermo Fisher.

Jul 02, 2020

Berkeley Lights: Greg Lucier

Greg Lucier has joined the board of directors of Berkeley Lights. He is the CEO of Corza Health and previously served as CEO of Nuvasive, where he remains chairman, and as chairman and CEO of Life Technologies. Prior to that, he held executive roles with General Electric. Lucier holds an MBA from Harvard Business School and a BS in industrial engineering from Pennsylvania State University.

Jun 29, 2020

Cergentis: Joris Schuurmans, Dirk Pollet, Maja Sanders

Cergentis of Utrecht, the Netherlands, this week announced a number of new appointments. Joris Schuurmans has become the firm's CEO, replacing Jan Dekker. Schuurmans joins Cergentis from Skyline Dx, where he led the melanoma program. Previously, he held senior executive positions at Biocartis and at MyCartis.

Further, Dirk Pollet and Maja Sanders have joined the company's supervisory board. Pollet is CEO of Enzyre and is the former CEO of Multiplicom, which was acquired by Agilent Technologies. Sanders holds supervisory roles at various organizations and has managerial experience in the private equity industry.

Jun 27, 2020

IsoPlexis: Peter Siesel

IsoPlexis has appointed Peter Siesel as chief commercial officer. Siesel joins IsoPlexis from Tecan, where he most recently served as senior vice president of sales and was responsible for commercialization in the Americas.

Jun 23, 2020

NeoGenomics: Cynthia Dieter

NeoGenomics announced the appointment of Cynthia Dieter as chief accounting officer and controller, effective June 22. Before coming to NeoGenomics, Dieter was the senior director of corporate accounting at Viasat. She has also served in multiple roles at DJO Global, including VP and assistant corporate controller, VP and vista controller, and director of financial reporting and planning. 

In addition, Dieter has been the manager of financial reporting at Captiva Software and audit manager for Ernst and Young. 

Jun 19, 2020

Guardant Health: Vijaya Gadde

Guardant Health has appointed Vijaya Gadde to serve on its Board of Directors. Gadde is Twitter's chief legal officer leading its legal, public policy, and trust and safety teams globally. Prior to joining Twitter in 2011, she was senior director, legal at Juniper Networks. Before that, she worked for nearly a decade at Wilson Sonsini Goodrich & Rosati. Gadde serves on the Board of Trustees of NYU Law School and the Board of Directors of Mercy Corps. She is also a co-founder of #Angels, an investment collective focused on funding diverse and ambitious founders pursuing bold ideas. She earned a JD from New York University School of Law and a BS in industrial and labor relations from Cornell University.

Jun 18, 2020

T2 Biosystems: Thierry Bernard, Ninfa Saunders, Robin Toft

T2 Biosystems has appointed Thierry Bernard, Ninfa Saunders, and Robin Toft to its board of directors. Bernard currently serves as CEO of Qiagen, Saunders is president and CEO of Navicent Health, and Toft is founder and CEO of Toft Group and previously served as senior vice president of commercial operations at Roche Molecular Diagnostics. T2 Biosystems also announced that Michael CimaAdrian Jones, and Stanley Lapidus will be leaving the firm's board of directors.

Jun 18, 2020

Waters: Christopher O'Connell

Christopher O'Connell will step down as president, CEO, and a member of the board of directors of Waters, the firm announced this week. Waters said that it has hired an executive search firm to identify a new CEO and that O'Connell will serve as an advisor until the end of this year to support the transition. O'Connell has served as president and CEO of Waters for the past five years, succeeding the firm's long-time leader Doug Berthiaume. According to terms of O'Connell's separation agreement, he will receive a cash severance in the amount of $4,252,500, payable over a two-year period following termination of employment and a bonus for calendar year 2020 based on the company's performance.

Jun 17, 2020

IonPath: Brad Nelson

IonPath has appointed Brad Nelson as senior vice president of marketing and corporate strategy. Nelson will lead marketing, product management, and application functions related to the company's multiplexed ion beam Imaging technology. Nelson most recently served as VP of marketing at Magnolia Medical Technologies. Prior to that he was head of marketing and director of corporate development at Labcyte (now part of Danaher). He also previously led marketing efforts at Velocity11, which was acquired by Agilent.

Jun 17, 2020

Phase Genomics: Kayla Young

Phase Genomics, a University of Washington spinout providing proximity-ligation next-generation sequencing solutions for metagenome assembly, has appointed Kayla Young as its chief operating officer. Young joined Phase Genomics in 2017 as director of operations. She also has previous experience at Life Science Washington, and received a PhD in molecular physiology and biophysics from Vanderbilt University in 2016.

Jun 15, 2020

Laboratory for Advanced Medicine: Samuel Tong

Laboratory for Advanced Medicine has appointed Samuel Tong as CEO for its operations in China. He joins the company from medical research organization NAMSA where he was vice president and general manager of the Asia-Pacific region. Prior to that, he was VP and GM for greater China at Qiagen. Tong was also business unit director of diagnostics systems for greater China at Becton Dickinson, and country manager of China at Abbott Vascular.

Jun 15, 2020

Foundation Medicine: Geoffrey Oxnard

Roche subsidiary Foundation Medicine announced Geoffrey Oxnard has been appointed vice president, global medical lead for the firm's liquid biopsy portfolio, effective immediately. In the role, he'll define research and a liquid biopsy-focused discovery roadmap while investigating novel applications of liquid biopsy approaches to improve cancer research and care.

Oxnard previously served as a thoracic oncologist and clinical investigator at the Dana-Farber Cancer Institute at Harvard Medical School, and he'll continue seeing patients part-time at the institute. His recent research has focused on the clinical application of liquid biopsy technologies to understand drug resistance for selecting targeted therapies and detecting occult cancer. 

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.